Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Oct 15 - Oct 20
Outcomes Primary and Secondary Outcome Patients in the semaglutide study arm experienced a significantly lower rate of the primary outcome (cardiovascular composite end-point) (6.5% vs 8.0%, HR 0.80 (95% CI 0.72-0.90) No significant difference in rates of cardiac death (HR 0.85, 95% CI 0.71-1.01) however significantly lower rates of heart failure (HR 0.82, 95% CI 0.71-0.96) and all-cause mortality (HR 0.81, 95% CI 0.71-0.93) Adverse Events Rates and types of adverse events were fairly similar between control and intervention groups Permanent premature discontinuation of semaglutide or placebo occurred in 2351 patients (26.7%) in the semaglutide group and 2078 (23.6%) in the placebo group In obese and overweight patients with cardiovascular comorbidities but without diabetes, treatment with weekly semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months
What's in the medication
Monica Bonakdar manages dosing and monitoring, and our team builds a treatment plan that covers nutrition targets, movement you can keep, sleep, and check-ins that prevent drift
Telehealth Costs Breakdown Compounded Medications (Telehealth): TrimRx Pricing : Semaglutide: $199/month Tirzepatide: $349/month Includes: Initial consultation Medication All injection supplies Shipping Ongoing follow-up appointments Access to medical support No hidden fees or additional costs
"Timing of Glutathione Supplementation: Effects on Bioavailability." Antioxidants & Redox Signaling, 32(7), 456-468
